Genmab A/S (GMAB) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Do analysts rate ALNY or GMAB?

Alnylam Pharmaceuticals currently has a consensus price target of $216.19, suggesting a potential upside of 40.08%. Genmab A/S has a consensus price target of $48.50, suggesting a potential upside of 65.59%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Genmab A/S is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.59
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38

Does the media prefer ALNY or GMAB?

In the previous week, Alnylam Pharmaceuticals had 14 more articles in the media than Genmab A/S. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 11 mentions for Genmab A/S. Alnylam Pharmaceuticals' average media sentiment score of 0.64 beat Genmab A/S's score of 0.46 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Genmab A/S	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ALNY or GMAB more profitable?

Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 18.90% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-16.58%	N/A	-8.92%
Genmab A/S	30.74%	18.90%	16.83%

Which has more risk and volatility, ALNY or GMAB?

Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Does the MarketBeat Community favor ALNY or GMAB?

Alnylam Pharmaceuticals received 948 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 60.68% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1090 76.17%	Underperform Votes 341 23.83%
Genmab A/S	Outperform Votes 142 60.68%	Underperform Votes 92 39.32%

Which has stronger valuation and earnings, ALNY or GMAB?

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$1.83B	10.68	-$440.24M	-$2.68	-57.59
Genmab A/S	$2.39B	8.10	$631.91M	$1.20	24.41

Do insiders and institutionals hold more shares of ALNY or GMAB?

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.